廣汽集團(02238.HK)引資控股股東投資聯營Chenqi Technology
廣汽集團(02238.HK)公佈,公司聯營Chenqi Technology作爲目標公司,與公司控股股東廣汽工業及其他投資者等訂立認購協議。廣汽工業同意按總行權價約5,512.5萬美元認購1,725.9萬份認股權證。若該等認股權證獲悉數行使,廣汽工業可獲目標公司發行1,725.9萬股A輪優先股。
目前,集團間接持有目標公司35%股權。增資完成後,廣汽工業將持有目標公司約12.9%股權,而公司於目標公司間接持有之股權將由35%相應攤薄至約26.15%,目標公司於增資完成後仍爲集團聯營公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.